patent.fyi
Applications  /  US 2026/0355250
United States Patent Application Publication

US 2026/0355250 A1

Published
Nov 12, 2026
Filed
Aug 28, 2024
Earliest date on the face
Aug 28, 2023
Classification
A61K 35/28
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Extracorporeal photopheresis

What ifWhat if the third-line intervention used extracorporeal photopheresis of the recipient's circulating leukocytes?
Claim language“mesenchymal lineage precursor or stem cells”

An apheresis circuit collects a leukocyte-rich fraction, mixes it with a photosensitizer, and exposes it to ultraviolet A light before reinfusion. The light-activated compound induces apoptosis in exposed cells, and their clearance modulates the recipient's immune response.

1.2Second-line cell therapy

What ifWhat if the mesenchymal cells were administered as second-line therapy after an inadequate response to initial systemic corticosteroids?
Claim language“a third line of therapy”

The cell infusion begins when clinical assessment shows an inadequate response to the first systemic regimen. Serial assessment of involved organs tracks the response to the second-line regimen.

1.2Fourth-line cell therapy

What ifWhat if the mesenchymal cells were administered as fourth-line therapy after three unsuccessful systemic regimens?
Claim language“a third line of therapy”

The cell infusion begins after reassessment documents persistent active GvHD following the third systemic regimen. Organ-specific measures such as stool volume and serum bilirubin track subsequent changes in gastrointestinal and hepatic disease.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Third line treatment in a veterinary setting

A veterinary transplant service uses a species-matched mesenchymal stromal cell suspension for dogs with graft-versus-host disease following donor hematopoietic cell transplantation. The treatment record identifies the first two regimens and documents the clinical response to each. The service records the cell infusion as the third regimen and tracks the affected organs at follow-up visits.

Component substitution

Adipose tissue as the cell source

Culture-expanded adipose-derived mesenchymal stromal cells replace bone-marrow-derived mesenchymal stromal cells in the infusion composition. The manufacturing workflow isolates the stromal fraction from donor adipose tissue, expands the adherent cells, and formulates the harvested cells as a sterile suspension. The infusion record links the administered lot to the third treatment line.

Parameter or scale variation

Three fixed intervals for response assessment

The third-line treatment record uses the first cell infusion as day 0 and schedules response assessments on days 7, 14, and 28. A baseline assessment before infusion records skin involvement, daily stool output, and serum bilirubin. Each follow-up assessment captures the same measurements and reports changes from baseline by organ.

Combination with existing systems

Cell lot tracking through infusion records

A cell processing laboratory connects its lot inventory system to the infusion service's electronic administration record. The laboratory transmits each lot's identifier, release status, viable cell count, and expiration time. A bedside scan checks the container against the assigned lot and active third-line order, then stores the lot identifier in the administration record.

Automated or data-driven variant

Automated review of prior treatment records

A rules engine reads medication administration records and structured treatment summaries to identify completed regimens for graft-versus-host disease. It groups drugs by documented regimen identifier and counts only regimens with a recorded stop date and response assessment. When two regimens have a documented inadequate response, the engine creates a review task and links the supporting records.

Automated cell counting before infusion

An imaging cell counter measures total and viable cells in a mixed sample taken from the prepared infusion suspension. The instrument uses a membrane-exclusion dye and reports viable cells per milliliter to the preparation workstation. The workstation divides the prescribed viable cell count by the measured concentration to calculate the volume to withdraw and records the measurement with the lot identifier.

Specific version of a part

Marrow-derived stromal cell suspension

Adherent mesenchymal stromal cells from donor bone marrow are expanded in culture and suspended in an isotonic carrier. The suspension is administered intravenously, with the dose expressed as viable cells per kilogram of recipient body weight.

Umbilical cord stromal cell suspension

Mesenchymal stromal cells are isolated from the connective tissue of a donated umbilical cord, expanded in culture, and cryopreserved in aliquots. An aliquot is thawed for infusion, and a post-thaw cell count and viability measurement determine the viable cell dose.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2022/0160776 A1
Published
May 26, 2022
Filed
Jan 28, 2020
Class
A61K 35/28
Document BUS 2023/0104108 A1
Published
Apr 6, 2023
Filed
Mar 11, 2021
Class
A61K 35/28
Claim 1
Document A
Document B
1.1administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs)
A method of treating or preventing gastrointestinal (GI) bleeding in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
A · US 2022/0160776 A1 · claim 1
The present disclosure relates to method of treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
B · US 2023/0104108 A1 · abstract
1.2wherein the MLPSCs are administered to the subject as a third line of therapy.
Accordingly, in a first example, the present disclosure relates to a method of treating or preventing inflammatory bowel disease in a human subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs), wherein the subject is refractory to at least one biologic therapy. In an example, the subject is refractory to a single biologic therapy.
B · US 2023/0104108 A1 · ¶ 5

An empty cell means only that no passage was reproduced there.

Statements in these documents
Accordingly, methods for treating or preventing gastrointestinal bleeding are required.
A · US 2022/0160776 A1 · ¶ 3
Preclinical cardiac studies performed with mesenchymal lineage precursor cells have demonstrated unexpectedly that administration of the cells to patients with left ventricular assisted device complications leads to a reduction in gastrointestinal (GI) bleeding and related hospitalization.
A · US 2022/0160776 A1 · ¶ 4
Accordingly, there remains an unmet therapeutic need in patients with IBD and/or its associated conditions or symptoms with new treatment options being required.
B · US 2023/0104108 A1 · ¶ 4
The present inventors have surprisingly identified that early disease remission (day 28) can be achieved in subjects with inflammatory bowel disease that are refractory to at least one biologic therapy.
B · US 2023/0104108 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355250 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355250/, SHA-256 c8493307d8b7251ba625a6cd14c6bcb41cbfadf33b18827606b888b5608d0196
First published
Permanent addresshttps://patent.fyi/US20260355250/
Content fingerprint (SHA-256)c8493307d8b7251ba625a6cd14c6bcb41cbfadf33b18827606b888b5608d0196
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi